# Providing Regulatory Submissions in Alternate Electronic Format Guidance for Industry:  Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/providing-regulatory-submissions-in-alternate-electronic-format-guidance-for-industry-guidance-for-industry/c95b38e3-1b57-413c-b3fc-da380f4218da

> FDA guidance document: Providing Regulatory Submissions in Alternate Electronic Format Guidance for Industry:  Guidance for Industry. Issue date: June 24, 2022. Get complete insights and analysis.

---

## Details

- Title: Providing Regulatory Submissions in Alternate Electronic Format Guidance for Industry:  Guidance for Industry
- Communication Type: Guidance Document
- Product Type: biologics
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2022-06-24
- Last Changed: 2022-06-24
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2020-D-0420">FDA-2020-D-0420</a>

## Related Documents

- [Drug-Drug Interaction Assessment for Therapeutic Proteins Guidance for Industry:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/drug-drug-interaction-assessment-for-therapeutic-proteins-guidance-for-industry-guidance-for-industry/2a0a5163-7a5f-4b3c-9eef-d94d670b6733)
- [E8(R1) General Considerations for Clinical Studies](https://www.globalkeysolutions.net/guidances/guidance-document/e8r1-general-considerations-for-clinical-studies/c5e52286-b058-4b0f-b1f2-e589be1aaf84)
- [Clinical Pharmacology Considerations for Antibody-Drug Conjugates  Guidance for Industry:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/clinical-pharmacology-considerations-for-antibody-drug-conjugates-guidance-for-industry-guidance-for-industry/ee3ed09c-6580-489f-bb06-0e93f612d604)